Clinical Trial Update: A Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Protein BG505 SOSIP.GT1.1 Gp140 Vaccine, Adjuvanted in Healthy, HIV-uninfected Adults [Phase 1]

View source ↗

Summary

This Phase 1 trial update reports completion of a study evaluating the safety and immunogenicity of the recombinant HIV-1 BG505 SOSIP.GT1.1 gp140 vaccine with a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• BG505 SOSIP.GT1.1 gp140 vaccine (recombinant HIV-1 envelope gp140 vaccine BG505 SOSIP.GT1.1)

Snippet

Sponsor: International AIDS Vaccine Initiative | Conditions: HIV Infections | Phase 1 | Status: COMPLETED